A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Foralumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Tiziana Life Sciences
Most Recent Events
- 06 May 2025 According to a Tiziana Life Sciences media release, this trial is expected to reach top line data read out at the end of 2025.
- 23 Apr 2025 According to a Tiziana Life Sciences media release, dosing has commenced at the fourth clinical site The University of Massachusetts (UMass).
- 02 Apr 2025 According to a Tiziana Life Sciences media release, company announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, and company expects the blinded portion of the trial to be completed by the end of 2025.